Stalled at the FDA, Am­i­cus adds a pre­clin­i­cal rare dis­ease drug in back-end­ed $90M deal

Am­i­cus Ther­a­peu­tics $FOLD has snagged a pre­clin­i­cal drug in a small biotech buy­out, beef­ing up its slim pipeline at a time that the com­pa­ny is still as­sess­ing just how bad­ly its lead drug may have stalled in front of the FDA.

The Cran­bury, NJ-based biotech ac­quired Mi­aMed for $1.8 mil­lion in cash, $4.7 mil­lion in Am­i­cus stock and up to $83 mil­lion in de­vel­op­ment and com­mer­cial­iza­tion mile­stones. The bulk of the mon­ey is back-end­ed to the com­mer­cial­iza­tion stage.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.